Objective To explore the value of imatinib for new diagnostic and treatment failure in human recombinant interferon α2b in the treatment of patients with chronic with leukemia.Methods127 cases of patients with chronic myelogenous leukemia in our hospital were randomly selected as the object of this study and were divided into group A and group B, 78 patients were newly diagnosed patients, 49 patients have failed the treatment of recombinant human interferon α2b. according to the type of patients, group A was newly diagnosed group, group B was the group of treatment failure in a recombinant human interferon α2b, Two groups of patients were treated with imatinib, to compare and analyze the curative effect.Results After 6 months and 12 months of treatment, the cell genetic response rate, partial response rate of group A was higher than those of group B. In the side effect, the diarrhea, blood cell reduction and the incidence rate of anemia of group A were lower than those of B group,P<0.05.Conclusion In the clinical treatment of patients with chronic myeloid leukemia, the curative effect of imatinib for patients with the treatment failure in human recombinant interferon α2b was lower than that for patients with newly diagnosed, which was higher incidence rate of side effects. The clinical management in CML should use imatinib therapy as early as possible, and the patients of failure or resistant of treatment in human recombinant interferon α2b should use imatinib therapy as early as possible to control the condition.%目的：探索伊马替尼对于新诊断与重组人干扰素α2b治疗失败的慢性随行白血病患者的治疗价值。方法随机选取在我院收治的慢性髓性白血病患者127例作为本次研究的对象，其中有78例患者为新诊断患者，49例患者为重组人干扰素α2b治疗失败的患者，根据患者的类型分成A组与B组，其中A组患者为新诊断组，B组为重组人干扰素α2b治疗失败组，对两组患者均采用伊马替尼治疗，对比分析治疗效果。结果治疗6个月和治疗12个月，A组患者的细胞遗传学完全反应率、部分反应率均高于B组。在毒副作用上，A组患者的腹泻、血细胞减少、贫血的发生率均低于B组，差异具有统计学意义，P＜0.05。结论在慢性髓性白血病患者的临床治疗中，重组人干扰素α2b治疗失败患者用伊马替尼治疗的效果低于新诊断患者的治疗效果，且毒副作用发生率更高，临床上对于CML治疗应及早使用伊马替尼治疗，而对于重组人干扰素α2b治疗失败或是出现耐药性的患者应及早采用伊马替尼治疗，控制病情。
展开▼
